Soligenix Featured in Editorial on Growing Need for Rare Disease Therapies Amid Aging Population

Soligenix Inc. (NASDAQ: SNGX) has been featured in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with rare disorders that often lack FDA-approved treatments, demand for novel therapies continues to grow. Soligenix is advancing late-stage programs including HyBryte™ for cutaneous T-cell lymphoma, now in its final confirmatory trial, positioning the Company at the intersection of scientific innovation and evolving national health-policy priorities focused on chronic and rare conditions.

The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the company's first-in-class innate defense regulator technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and SGX945 in Behçet's Disease.

Soligenix's Public Health Solutions business segment includes development programs for RiVax®, the company's ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola and CiVax™, the company's vaccine candidate for the prevention of COVID-19. The development of these vaccine programs incorporates the use of the company's proprietary heat stabilization platform technology known as ThermoVax®. This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency and the Biomedical Advanced Research and Development Authority.

The editorial placement comes as BioMedWire serves as a specialized communications platform with a focus on the latest developments in biotechnology, biomedical sciences and life sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.